TABLE 1.
Streptococcus agalactiae susceptibility profile and antibacterial activity of copaiba oil and kaurenoic acid.
| GBS isolate (serotype1) | Resistance genes1 | Susceptibility profile1 | Copaiba oil | Kaurenoic acid | |||
| DA | E | MIC (mg/mL) | MBC (mg/mL) | MIC (mg/mL) | MBC (mg/mL) | ||
| GBS ATCC 13813 (II) | – | S | S | 0.03 | 0.06 | 0.0125 | 0.03 |
| GBS 1 (V) | – | S | S | 0.03 | 0.06 | 0.0125 | 0.06 |
| GBS 2 (Ia) | – | S | S | 0.06 | 0.12 | 0.0125 | >0.1 |
| GBS 37 (Ia) | – | S | S | 0.06 | 0.12 | 0.0125 | >0.1 |
| GBS 46 (Ia) | mef (A/E) | S | R | 0.03 | 0.12 | 0.0125 | >0.1 |
| GBS 65 (V) | erm(A) | R | R | 0.03 | 0.06 | 0.0125 | 0.1 |
| GBS 66 (III) | erm(B) | R | R | 0.06 | 0.06 | 0.0125 | 0.1 |
| GBS 84 (V) | – | S | S | 0.06 | 0.06 | 0.0125 | 0.1 |
| GBS 89 (Ia) | – | S | S | 0.06 | 0.06 | 0.0125 | 0.1 |
| GBS 121 (Ia) | mef (A/E) | S | R | 0.06 | 0.06 | 0.0125 | 0.03 |
1Genotypic and phenotypic characterization of GBS isolates and erythromycin (E) and clindamycin (DA) susceptibility profile previously described (Otaguiri et al., 2013). MIC, minimal inhibitory concentration; MBC, minimum bactericidal concentration.